Kwality Pharmaceuticals Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1002639,
    "name": "Kwality Pharma",
    "stock_name": "Kwality Pharma",
    "full_name": "Kwality Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/kwality-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,142.00",
    "chg": 89.9,
    "chgp": "8.54%",
    "dir": 1,
    "prev_price": "1,052.10",
    "mcapval": "1,151.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 539997,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE552U01010",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "15.1 k",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/kwality-pharma-1002639-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Kwality Pharma technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-kwality-pharma-technically-bullish-or-bearish-3745645",
        "imagepath": "",
        "date": "2025-12-04 08:44:09",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Technical Trend Shift</strong></p>\n<p>As of 3 December 2025, Kwality Pharma’s technical trend shifted from mildly bearish to outright bearish. This change reflects growing caution among traders and technical analysts, who are observing increased selling pressure and weakening momentum. The transition to a bearish trend is significant as it signals a potential continuation of downward price movement in the near term.</p>\n<p>The daily moving averages reinforce this view, showing a bearish stance that suggests the stock is trading below key average price levels. Such a pattern often indicates that sellers are in control and that the stock may face resistance in mounting a sustained rally.</p>\n<p><strong>Technical Indicators Breakdown</strong></p>\n<p>Examining the key technical indicators..."
      },
      {
        "title": "Kwality Pharmaceuticals: Analytical Perspective Shifts Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/kwality-pharmaceuticals-downgraded-to-sell-amid-technical-weakness-and-growth-concerns-3745613",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/KwalityPharmace_mojoScore_3745613.png",
        "date": "2025-12-04 08:21:33",
        "description": "Kwality Pharmaceuticals has experienced a revision in its market assessment following a detailed review of its financial performance, valuation metrics, technical indicators, and overall quality parameters. This article explores the factors influencing the recent changes in the company’s evaluation, providing investors with a comprehensive understanding of the current landscape for this Pharmaceuticals & Biotechnology stock."
      },
      {
        "title": "Kwality Pharmaceuticals Faces Bearish Momentum Amid Technical Shifts",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/kwality-pharmaceuticals-faces-bearish-momentum-amid-technical-downgrade-3745511",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/KwalityPharmace_technicaldot_3745511.png",
        "date": "2025-12-04 08:11:40",
        "description": "Kwality Pharmaceuticals has experienced a notable shift in its technical momentum, with recent evaluation adjustments signalling a bearish trend across multiple timeframes. The stock’s price movement and key technical indicators suggest a cautious outlook as it navigates a challenging phase within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "How has been the historical performance of Kwality Pharma?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-kwality-pharma-3744768",
        "imagepath": "",
        "date": "2025-12-03 22:54:50",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Profit Trends</strong></p>\n<p>Kwality Pharma's net sales have shown considerable variation, peaking notably in the fiscal year ending March 2022 at ₹456.19 crores before moderating to ₹370.20 crores in March 2025. This peak was preceded by a steady rise from ₹139.30 crores in March 2020, reflecting a strong recovery and expansion phase. The total operating income mirrored this pattern, with no other operating income reported across the years.</p>\n<p>Operating profit (PBDIT) excluding other income surged to ₹171.67 crores in March 2022, a significant jump from ₹14.19 crores in March 2020, before settling at ₹80.39 crores in March 2025. The operating profit margin excluding other income peaked at 37.63% in March 2022, indicating a period of exceptional operational efficiency, thoug..."
      },
      {
        "title": "Kwality Pharmaceuticals Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/kwality-pharmaceuticals-technical-momentum-shifts-amid-mixed-market-signals-3734724",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/KwalityPharmace_technicaldot_3734724.png",
        "date": "2025-11-28 08:07:23",
        "description": "Kwality Pharmaceuticals has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish signals across key indicators. The stock’s recent price movements and technical parameters suggest a cautious market stance amid evolving trends in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Kwality Pharmaceuticals Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/kwality-pharmaceuticals-faces-technical-momentum-shift-amid-mixed-market-signals-3732568",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/KwalityPharmace_technicaldot_3732568.png",
        "date": "2025-11-27 08:07:44",
        "description": "Kwality Pharmaceuticals has experienced a notable shift in its technical momentum, reflecting a complex interplay of bearish and bullish signals across multiple timeframes. Recent evaluation adjustments indicate a transition from a sideways trend to a more bearish stance, with key indicators such as MACD, RSI, and moving averages providing a nuanced picture of the stock’s near-term trajectory."
      },
      {
        "title": "Kwality Pharmaceuticals Forms Death Cross, Signalling Potential Bearish Trend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/kwality-pharmaceuticals-forms-death-cross-signalling-bearish-trend-3731882",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/KwalityPharmace_dealthcross_3731882.png",
        "date": "2025-11-26 18:01:20",
        "description": "Kwality Pharmaceuticals has recently experienced a significant technical development as its 50-day moving average crossed below the 200-day moving average, forming what is commonly referred to as a Death Cross. This event often signals a shift towards a bearish trend, indicating potential long-term weakness in the stock’s price movement."
      },
      {
        "title": "Kwality Pharmaceuticals: Analytical Perspective Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/kwality-pharmaceuticals-downgraded-to-hold-amid-mixed-technical-and-valuation-signals-3727893",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/KwalityPharmace_mojoScore_3727893.png",
        "date": "2025-11-25 08:51:57",
        "description": "Kwality Pharmaceuticals has experienced a revision in its market assessment following a detailed evaluation across quality, valuation, financial trends, and technical indicators. This nuanced shift reflects a complex interplay of strong financial results tempered by evolving technical signals and valuation considerations within the pharmaceuticals sector."
      },
      {
        "title": "Kwality Pharmaceuticals Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/kwality-pharmaceuticals-faces-technical-momentum-shift-amid-market-volatility-3727621",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/KwalityPharmace_technicaldot_3727621.png",
        "date": "2025-11-25 08:13:19",
        "description": "Kwality Pharmaceuticals has experienced a notable shift in its technical momentum, reflecting a transition from a mildly bullish trend to a sideways movement. Recent market data and technical indicators reveal a complex picture for the pharmaceutical company, with mixed signals emerging from key metrics such as MACD, RSI, Bollinger Bands, and moving averages."
      }
    ],
    "total": 211,
    "sid": "1002639",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/kwality-pharmaceuticals-1002639"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
      "datetime": "02-Feb-2026",
      "details": "Cessation of Independent Directors upon completion of tenure.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Consideration And Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended On 31St December 2025.",
      "datetime": "02-Feb-2026",
      "details": "Kwality Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2026 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended on 31st December 2025.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Appointment Of Mr. Bhavesh Mahajan (DIN: 09614108) As Additional Independent Director Of The Company",
      "datetime": "28-Jan-2026",
      "details": "We wish to inform you that on the recommendation of Nomination and Remuneration Committee the Board of Directors of the Company at its meeting held today i.e. on January 28 2026 has inter alia considered and approved the appointment of Mr. Bhavesh Mahajan (DIN: 09614108) as Additional Independent Director of the Company who shall hold office for a period of five (5) consecutive years with effect from 28th January 2026 to 27th January 2031(both days inclusive) subject to approval of the shareholders of the Company.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Kwality Pharmaceuticals Ltd has declared <strong>6%</strong> dividend, ex-date: 05 Jan 17",
          "dt": "2017-01-05",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Kwality Pharmaceuticals Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 11 Oct 17",
          "dt": "2017-10-11",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Is Kwality Pharma technically bullish or bearish?

2025-12-04 08:44:09

Recent Technical Trend Shift As of 3 December 2025, Kwality Pharma’s technical trend shifted from mildly bearish to outright bearish. This change reflects growing caution among traders and technical analysts, who are observing increased selling pressure and weakening momentum. The transition to a bearish trend is significant as it signals a potential continuation of downward price movement in the near term. The daily moving averages reinforce this view, showing a bearish stance that suggests the stock is trading below key average price levels. Such a pattern often indicates that sellers are in control and that the stock may face resistance in mounting a sustained rally. Technical Indicators Breakdown Examining the key technical indicators...

Kwality Pharmaceuticals: Analytical Perspective Shifts Amid Mixed Financial and Technical Signals

2025-12-04 08:21:33

Kwality Pharmaceuticals has experienced a revision in its market assessment following a detailed review of its financial performance, valuation metrics, technical indicators, and overall quality parameters. This article explores the factors influencing the recent changes in the company’s evaluation, providing investors with a comprehensive understanding of the current landscape for this Pharmaceuticals & Biotechnology stock.

Kwality Pharmaceuticals Faces Bearish Momentum Amid Technical Shifts

2025-12-04 08:11:40

Kwality Pharmaceuticals has experienced a notable shift in its technical momentum, with recent evaluation adjustments signalling a bearish trend across multiple timeframes. The stock’s price movement and key technical indicators suggest a cautious outlook as it navigates a challenging phase within the Pharmaceuticals & Biotechnology sector.

How has been the historical performance of Kwality Pharma?

2025-12-03 22:54:50

Revenue and Profit Trends Kwality Pharma's net sales have shown considerable variation, peaking notably in the fiscal year ending March 2022 at ₹456.19 crores before moderating to ₹370.20 crores in March 2025. This peak was preceded by a steady rise from ₹139.30 crores in March 2020, reflecting a strong recovery and expansion phase. The total operating income mirrored this pattern, with no other operating income reported across the years. Operating profit (PBDIT) excluding other income surged to ₹171.67 crores in March 2022, a significant jump from ₹14.19 crores in March 2020, before settling at ₹80.39 crores in March 2025. The operating profit margin excluding other income peaked at 37.63% in March 2022, indicating a period of exceptional operational efficiency, thoug...

Kwality Pharmaceuticals Technical Momentum Shifts Amid Mixed Market Signals

2025-11-28 08:07:23

Kwality Pharmaceuticals has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish signals across key indicators. The stock’s recent price movements and technical parameters suggest a cautious market stance amid evolving trends in the Pharmaceuticals & Biotechnology sector.

Kwality Pharmaceuticals Technical Momentum Shifts Amid Mixed Market Signals

2025-11-27 08:07:44

Kwality Pharmaceuticals has experienced a notable shift in its technical momentum, reflecting a complex interplay of bearish and bullish signals across multiple timeframes. Recent evaluation adjustments indicate a transition from a sideways trend to a more bearish stance, with key indicators such as MACD, RSI, and moving averages providing a nuanced picture of the stock’s near-term trajectory.

Kwality Pharmaceuticals Forms Death Cross, Signalling Potential Bearish Trend

2025-11-26 18:01:20

Kwality Pharmaceuticals has recently experienced a significant technical development as its 50-day moving average crossed below the 200-day moving average, forming what is commonly referred to as a Death Cross. This event often signals a shift towards a bearish trend, indicating potential long-term weakness in the stock’s price movement.

Kwality Pharmaceuticals: Analytical Perspective Shifts Amid Mixed Market Signals

2025-11-25 08:51:57

Kwality Pharmaceuticals has experienced a revision in its market assessment following a detailed evaluation across quality, valuation, financial trends, and technical indicators. This nuanced shift reflects a complex interplay of strong financial results tempered by evolving technical signals and valuation considerations within the pharmaceuticals sector.

Kwality Pharmaceuticals Technical Momentum Shifts Amid Mixed Market Signals

2025-11-25 08:13:19

Kwality Pharmaceuticals has experienced a notable shift in its technical momentum, reflecting a transition from a mildly bullish trend to a sideways movement. Recent market data and technical indicators reveal a complex picture for the pharmaceutical company, with mixed signals emerging from key metrics such as MACD, RSI, Bollinger Bands, and moving averages.

View All News

Announcement

Announcement under Regulation 30 (LODR)-Change in Management

02-Feb-2026 | Source : BSE

Cessation of Independent Directors upon completion of tenure.

Board Meeting Intimation for Consideration And Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended On 31St December 2025.

02-Feb-2026 | Source : BSE

Kwality Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2026 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended on 31st December 2025.

Board Meeting Outcome for Appointment Of Mr. Bhavesh Mahajan (DIN: 09614108) As Additional Independent Director Of The Company

28-Jan-2026 | Source : BSE

We wish to inform you that on the recommendation of Nomination and Remuneration Committee the Board of Directors of the Company at its meeting held today i.e. on January 28 2026 has inter alia considered and approved the appointment of Mr. Bhavesh Mahajan (DIN: 09614108) as Additional Independent Director of the Company who shall hold office for a period of five (5) consecutive years with effect from 28th January 2026 to 27th January 2031(both days inclusive) subject to approval of the shareholders of the Company.

Corporate Actions

BOARD MEETING

No Upcoming Board Meetings

DIVIDEND

Kwality Pharmaceuticals Ltd has declared 6% dividend, ex-date: 05 Jan 17

SPLITS

No Splits history available

BONUS

Kwality Pharmaceuticals Ltd has announced 1:1 bonus issue, ex-date: 11 Oct 17

RIGHTS

No Rights history available

Name: MOJO Markets Private Limited (Research Entity) (SEBI Registration No. INH000021942) (CIN:U74900MH2015PTC264951)

Registered & Correspondence Address: Benefice Business House, Office No. 3B, 3rd Floor, C.S. 242, Mathuradas Mills Estate, N.M. Joshi Marg, Tulsi Pipe Road, Lower Parel West, Mumbai- 400013

For queries or grievances, please contact us on support@mojoinfinity.com, Phone : 022-35121239

"Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors."